Virtu Financial LLC Acquires 62,459 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Virtu Financial LLC raised its stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 319.2% in the first quarter, Holdings Channel reports. The fund owned 82,029 shares of the company’s stock after purchasing an additional 62,459 shares during the quarter. Virtu Financial LLC’s holdings in Actinium Pharmaceuticals were worth $642,000 at the end of the most recent reporting period.

Separately, Vanguard Group Inc. lifted its stake in Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ATNM has been the topic of a number of research reports. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, May 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Friday, July 26th. Finally, Stephens began coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.60.

Actinium Pharmaceuticals Price Performance

ATNM stock traded down $0.45 during trading on Friday, hitting $6.17. The company had a trading volume of 414,603 shares, compared to its average volume of 301,460. Actinium Pharmaceuticals, Inc. has a one year low of $4.00 and a one year high of $10.24. The stock has a market capitalization of $183.74 million, a PE ratio of -3.67 and a beta of 0.20.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.